{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T13:04:12Z","timestamp":1710248652158},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00108-013-3312-x","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T07:54:02Z","timestamp":1373961242000},"page":"1141-1151","source":"Crossref","is-referenced-by-count":11,"title":["Empfehlung zur Herzinsuffizienz"],"prefix":"10.1007","volume":"54","author":[{"given":"G.","family":"Hasenfu\u00df","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Wachter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"key":"3312_CR1","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","volume":"283","author":"ALLHAT","year":"2000","unstructured":"ALLHAT Collaborative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283:1967\u20131975","journal-title":"JAMA"},{"key":"3312_CR2","doi-asserted-by":"crossref","unstructured":"Anker SD, Comin Colet J, Filippatos G et\u00a0al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N\u00a0Engl J Med 361:2436\u20132448","DOI":"10.1056\/NEJMoa0908355"},{"key":"3312_CR3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1388-9842(03)00163-6","volume":"5","author":"Cohn","year":"2003","unstructured":"Cohn JN, Pfeffer MA, Rouleau J et\u00a0al (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5:659\u2013667","journal-title":"Eur J Heart Fail"},{"key":"3312_CR4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/CIRCULATIONAHA.112.125435","volume":"126","author":"Desai","year":"2012","unstructured":"Desai AS, Stevenson LW (2012) Rehospitalization for heart failure: predict or prevent? Circulation 126:501\u2013506","journal-title":"Circulation"},{"key":"3312_CR5","doi-asserted-by":"crossref","unstructured":"Echt DS, Liebson PR, Mitchell LB et\u00a0al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N\u00a0Engl J Med 324:781\u2013788","DOI":"10.1056\/NEJM199103213241201"},{"key":"3312_CR6","doi-asserted-by":"crossref","unstructured":"Edelmann F, Gelbrich G, D\u00fcngen HD et\u00a0al (2011) Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J\u00a0Am Coll Cardiol 58:1780\u20131791","DOI":"10.1016\/j.jacc.2011.06.054"},{"key":"3312_CR7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG et\u00a0al (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781\u2013791","journal-title":"JAMA"},{"key":"3312_CR8","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","volume":"J","author":"Ekman","year":"2011","unstructured":"Ekman I, Chassany O, Komajda M et\u00a0al (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart\u00a0J 32:2395\u20132404","journal-title":"Eur Heart"},{"key":"3312_CR9","first-page":"1787","volume":"J","author":"McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD et\u00a0al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart\u00a0J 33:1787\u20131847","journal-title":"Eur Heart"},{"key":"3312_CR10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD et\u00a0al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail 14:803\u2013869","journal-title":"Eur J Heart Fail"},{"key":"3312_CR11","doi-asserted-by":"crossref","unstructured":"Feldman T, Kar S, Rinaldi M et\u00a0al (2009) Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J\u00a0Am Coll Cardiol 54:686\u2013694","DOI":"10.1016\/j.jacc.2009.03.077"},{"key":"3312_CR12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12181-013-0491-6","volume":"7","author":"Hasenfu\u00df","year":"2013","unstructured":"Hasenfu\u00df G, Anker S, Bauersachs J et\u00a0al (2013) Kommentar zu den Leitlinien der Europ\u00e4ischen Gesellschaft f\u00fcr Kardiologie (ESC) zur Diagnostik und Behandlung der akuten und chronischen Herzinsuffizienz. Kardiologe 7:105\u2013114","journal-title":"Kardiologe"},{"key":"3312_CR13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","volume":"11","author":"Hernandez","year":"2011","unstructured":"Hernandez AV, Usmani A, Rajamanickam A et\u00a0al (2011) Thiazolidinediones and risk of heart failure in patients with or at high risk of type\u00a02 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 11:115\u2013128","journal-title":"Am J Cardiovasc Drugs"},{"key":"3312_CR14","doi-asserted-by":"crossref","unstructured":"K\u00f8ber L, Torp-Pedersen C, McMurray JJ et\u00a0al (2008) Increased mortality after dronedarone therapy for severe heart failure. N\u00a0Engl J Med 358:2678\u20132687","DOI":"10.1056\/NEJMoa0800456"},{"key":"3312_CR15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1067\/mhj.2002.123575","volume":"J","author":"Koelling","year":"2002","unstructured":"Koelling TM, Aaronson KD, Cody RJ (2002) Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart\u00a0J 144:524\u2013529","journal-title":"Am Heart"},{"key":"3312_CR16","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(04)16299-5","volume":"363","author":"Mamdani","year":"2004","unstructured":"Mamdani M, Juurlink DN, Lee DS et\u00a0al (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363:1751\u20131756","journal-title":"Lancet"},{"key":"3312_CR17","doi-asserted-by":"crossref","unstructured":"Moss AJ, Hall WJ, Cannom DS et\u00a0al (2009) Cardiac-resynchronization therapy for the prevention of heart failure events. N\u00a0Engl J Med 361:1329\u20131338","DOI":"10.1056\/NEJMoa0906431"},{"key":"3312_CR18","first-page":"269","volume":"106","author":"Neumann","year":"2009","unstructured":"Neumann T, Biermann J, Erbel R et\u00a0al (2009) Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspective. Dtsch Arztebl Int 106:269\u2013275","journal-title":"Dtsch Arztebl Int"},{"key":"3312_CR19","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.2009.454","volume":"301","author":"O","year":"2009","unstructured":"O\u2019Connor CM, Whellan DJ, Lee KL (2009) Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301:1439\u20131450","journal-title":"JAMA"},{"key":"3312_CR20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/eurjhf\/hfr017","volume":"13","author":"Piepoli","year":"2011","unstructured":"Piepoli MF, Conraads V, Corra U (2011) Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail 13:347\u2013357","journal-title":"Eur J Heart Fail"},{"key":"3312_CR21","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ et\u00a0al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N\u00a0Engl J Med 341:709\u2013717","DOI":"10.1056\/NEJM199909023411001"},{"key":"3312_CR22","unstructured":"Pocket-Leitlinien der Deutschen Gesellschaft f\u00fcr Kardiologie. http:\/\/www.escardio.org oder http:\/\/www.dgk.org"},{"key":"3312_CR23","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","volume":"309","author":"Redfield","year":"2013","unstructured":"Redfield MM, Chen HH, Borlaug BA et\u00a0al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309:1268\u20131277","journal-title":"JAMA"},{"key":"3312_CR24","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1001\/archinternmed.2011.247","volume":"171","author":"Sipahi","year":"2011","unstructured":"Sipahi I, Carrigan TP, Rowland DY et\u00a0al (2011) Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy. Meta-analysis of randomized controlled trials. Arch Intern Med 171:1454\u20131462","journal-title":"Arch Intern Med"},{"key":"3312_CR25","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B et\u00a0al; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase\u00a02 double-blind randomised controlled trial. Lancet 380:1387\u20131395","journal-title":"Lancet"},{"key":"3312_CR26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M et\u00a0al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875\u2013885","journal-title":"Lancet"},{"key":"3312_CR27","doi-asserted-by":"crossref","unstructured":"Swedberg K, Young JB, Anand IS (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N\u00a0Engl J Med 368:1210\u20131219","DOI":"10.1056\/NEJMoa1214865"},{"key":"3312_CR28","doi-asserted-by":"crossref","unstructured":"Tang AS, Wells GA, Talajic M (2010) Cardiac-resynchronization therapy for mild-to-moderate heart failure. N\u00a0Engl J Med 363:2385\u20132395","DOI":"10.1056\/NEJMoa1009540"},{"key":"3312_CR29","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","volume":"J","author":"Tardif","year":"2011","unstructured":"Tardif JC, O\u2019Meara E, Komajda M (2011) Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart\u00a0J 32:2507\u20132515","journal-title":"Eur Heart"},{"key":"3312_CR30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","volume":"381","author":"Teerlink","year":"2013","unstructured":"Teerlink JR, Cotter G, Davison BA et\u00a0al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomized, placebo-controlled trial. Lancet 381:29\u201339","journal-title":"Lancet"},{"key":"3312_CR31","doi-asserted-by":"crossref","unstructured":"The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N\u00a0Engl J Med 327:685\u2013691","DOI":"10.1056\/NEJM199209033271003"},{"key":"3312_CR32","unstructured":"Zannad F, McMurray JJ, Krum H et\u00a0al (2010) Eplerenone in patients with systolic heart failure and mild symptoms. N\u00a0Engl J Med 361:11\u201321"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3312-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-013-3312-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3312-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:17:36Z","timestamp":1558585056000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-013-3312-x"}},"subtitle":["Was gibt es Neues?"],"short-title":[],"issued":{"date-parts":[[2013,7,18]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["3312"],"URL":"https:\/\/doi.org\/10.1007\/s00108-013-3312-x","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,18]]}}}